Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Trading Up 1.8 %

Shares of ATOS stock opened at $0.82 on Friday. The stock has a market capitalization of $106.49 million, a price-to-earnings ratio of -3.75 and a beta of 1.01. Atossa Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.72. The stock’s 50-day moving average price is $0.71 and its 200-day moving average price is $0.94.

Analyst Upgrades and Downgrades

ATOS has been the subject of a number of research reports. Ascendiant Capital Markets increased their target price on Atossa Therapeutics from $7.00 to $7.25 and gave the company a “buy” rating in a research report on Monday, April 21st. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research note on Wednesday, March 26th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE lifted its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,475 shares of the company’s stock after purchasing an additional 37,809 shares during the quarter. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.